Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Tumor-Agnostic 1Head & Neck 1Endocrine 1Breast 1

Conditions

Lymphoma, Follicular 2Renal Insufficiency 1Hypertension 1

Interventions

Rituximab 702Cyclophosphamide 645Vincristine 353Doxorubicin 309Etoposide 305Cytarabine 271Filgrastim 250Prednisone 249Methotrexate 241fludarabine phosphate 231Dexamethasone 209fludarabine 184Peripheral Blood Stem Cell Transplantation 166Radiotherapy 161Granulocyte Colony-Stimulating Factor 145Lenalidomide 144Bendamustine Hydrochloride 142Bortezomib 127Melphalan 126ibrutinib 111Busulfan 111Mycophenolic Acid 108Whole-Body Irradiation 107Tacrolimus 96Cyclosporine 87Gemcitabine 82Ifosfamide 80Calcium Dobesilate 80Alemtuzumab 80Leucovorin 78

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × sacubitril and valsartan sodium hydrate drug combination × Lymphoid × Clear all
NCT06236061 2026-01-13

Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy

Novartis

Phase 3 Completed
718 enrolled
Lymphoid

Hypertension, Lymphoma, Follicular

NCT01569815 2015-10-19

Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function

Novartis

Phase 1 Completed
32 enrolled 16 charts
Lymphoid

Lymphoma, Follicular, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡